Prognostic value of response after upfront therapy for acute GVHD - Wikidata - wikimedia - TriplyDB

Prognostic value of response after upfront therapy for acute GVHD

Prognostic value of response after upfront therapy for acute GVHD

http://www.wikidata.org/entity/Q33964701

about

Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Steroid-Refractory Acute GVHD: Predictors and Outcomes.Plasma biomarkers of lower gastrointestinal and liver acute GVHD.Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Have we improved in preventing and treating acute graft-versus-host disease?Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.Treatment and management of graft-versus-host disease: improving response and survival.Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.Assessing response of therapy for acute and chronic graft-versus-host disease.State-of-the-art acute and chronic GVHD treatment.Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD.Prognosis of grade 3-4 acute GVHD continues to be dismal.Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.

P2860

Q34093615-95A9940C-8F26-4925-A26C-B8B833B18AA1 Q35550596-48005654-7B1A-4E06-BAFD-7DE34649C8D8 Q35891657-7E49B43A-B8D1-47F5-9347-06D137EF1626 Q35909700-DCF27723-7E29-458A-B0FB-9533B415826D Q36113205-1AFC8A27-F476-4FFA-9847-05FE0413DB93 Q36203692-1100F10F-AA67-44DA-8C94-19DBC2ECB9F4 Q36821646-04B1DC7E-ABE8-45DF-BD23-D0CDBACFF2C4 Q37371836-99D5C1B6-2B77-42C2-A44C-97EDCD4908DA Q37552088-F398769C-C275-4F9F-ACCF-C022C4EC95E6 Q37618997-F6C428BB-01B2-4264-92B5-BE46077C40DC Q37624271-533E45B9-3713-4BF2-A118-098EF614ABE8 Q37696092-43E487D3-9679-43AC-B805-7BCBDFB1D1B9 Q38078431-4757244A-35EF-40E5-888A-732D9FC8D579 Q38416376-D38C60B6-E97D-4C1B-BDAE-0464F8D9D3AC Q42270601-6D425EC6-F249-42E9-9B31-EBFFDD4E99BC Q48146759-2FBC9968-620D-400C-B62F-6A129EB1CDAA Q48231285-06CE6EC7-BB64-4D39-BF51-980BBD250ED7 Q52653321-698279AF-33AE-498E-AC2E-68AB3B008BF5 Q53110668-959463FD-16F9-417A-AB7A-86E12972B35D Q55319551-27BE72DE-D95D-441B-8212-1C9A334AA6D1

P2860

Prognostic value of response after upfront therapy for acute GVHD

http://www.wikidata.org/entity/Q33964701

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Prognostic value of response after upfront therapy for acute GVHD

@ast

Prognostic value of response after upfront therapy for acute GVHD

@en

type

label

Prognostic value of response after upfront therapy for acute GVHD

@ast

Prognostic value of response after upfront therapy for acute GVHD

@en

prefLabel

Prognostic value of response after upfront therapy for acute GVHD

@ast

Prognostic value of response after upfront therapy for acute GVHD

@en

P1433

Q33964701-BDC81D7E-42B0-469E-8CC1-302584A74E7A

P1476

Q33964701-0307EEED-DAFA-46BA-8B89-A82E80931079

P2093

Q33964701-11CA08F6-03C2-4DEC-8DA3-20519089C3FF

Q33964701-1CD353C8-5CA5-4772-9B5F-95C5DDC4F925

Q33964701-24AC871F-6409-4F8B-BA26-BABE93FCCB0A

Q33964701-6BDAF260-595C-4DAA-8A09-0CD72BA6234F

Q33964701-7A99D3B5-3546-4440-AD1E-32C8B4125BD0

Q33964701-89FF897E-EC3E-47AB-882F-44E007E3D6EA

Q33964701-98D5ABD6-5745-4721-B374-85384B920558

Q33964701-E96227FD-78C5-4C69-8004-6A182A16F6E8

P2860

Q33964701-0FF2AA78-BA05-4C8E-AAA4-97A47DCF35BB

Q33964701-29F5FA29-B379-4891-99D7-2E83AAD5F12D

Q33964701-3BED9E19-78B1-470D-8F62-1A7503A580B8

Q33964701-40DC6E68-0ED0-4539-9B56-3B27C72ABFA9

Q33964701-540D3EE5-5551-45C9-AE60-B7C18F9BEB89

Q33964701-8727EA20-C793-419E-852D-B805B759E45B

Q33964701-9909539D-DC91-4679-935F-ED1C417F777D

Q33964701-ABDCEA5E-B515-48D0-81FE-8C611107B687

Q33964701-C148E3F4-D125-4F9D-BA39-52C0C89FD481

Q33964701-C8662687-C754-4EA4-9972-F2CAF44C113B

P2888

Q33964701-30472103-9896-4580-A8EB-1ABDE5796FAA

P304

Q33964701-EDBA681C-F67E-496F-A1BA-973D94959843

P31

Q33964701-394D60F3-1C9B-4A5A-AB6A-BCD1F8A8AE51

P356

Q33964701-FBD81ED7-BFDC-4C81-A43E-6A8D441C9EE6

P407

Q33964701-6CE85A16-2F10-4B95-BD08-BC79E7F866E3

P433

Q33964701-5166EC1D-8537-4DE4-8717-12A74EC1447C

P478

Q33964701-D5B4CD0E-6A3B-404A-AFEF-7858D9F3E70E

P577

Q33964701-22761C7F-BFC5-4961-8120-C734F0E0663B

P5875

Q33964701-7C51D190-A97D-4EF2-8950-49DFDA7CDA56

P6179

Q33964701-FD828C33-8945-4EFD-9C4F-76C048F27D74

P698

Q33964701-1FB8CA5B-1618-4130-A756-DC4834527961

P932

Q33964701-1505FFFD-FBAA-4B16-AAC3-98074E01823C

P356

P1433

Bone Marrow Transplantation

P1476

Prognostic value of response after upfront therapy for acute GVHD

@en

P2093

A M Alousi

http://www.w3.org/2001/XMLSchema#string

A Rashid

http://www.w3.org/2001/XMLSchema#string

D R Couriel

http://www.w3.org/2001/XMLSchema#string

G Rondon

http://www.w3.org/2001/XMLSchema#string

G-J Okoroji

http://www.w3.org/2001/XMLSchema#string

R E Champlin

http://www.w3.org/2001/XMLSchema#string

R M Saliba

http://www.w3.org/2001/XMLSchema#string

S Giralt

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of graft-versus-host disease on survival.

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement

A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.

Graft-versus-host disease treatment: predictors of survival.

Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR

Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease.

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

1994 Consensus Conference on Acute GVHD Grading

An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.

The best endpoint for acute GVHD treatment trials.

P2888

P304

125-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2011.41

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50304815

http://www.w3.org/2001/XMLSchema#string

P6179

1022226549

http://www.w3.org/2001/XMLSchema#string

P698

21383686

http://www.w3.org/2001/XMLSchema#string

P932

4114039

http://www.w3.org/2001/XMLSchema#string